Core Insights - Sotera Health Company has appointed Kenneth D. Krause as a new independent director to its Board of Directors, enhancing its governance and strategic capabilities [1][3] Group 1: Appointment of Kenneth D. Krause - Kenneth D. Krause has extensive experience as a public company chief financial officer, having served at Rollins, Inc. and MSA Safety Incorporated, where he led initiatives that improved growth and profitability [2][3] - Krause will serve on the Audit Committee and the Litigation Committee of the Board, bringing expertise in corporate strategy, capital allocation, and public company governance [2][3] Group 2: Resignation of Constantine S. Mihas - Constantine ("Dean") S. Mihas has resigned from the Board effective March 16, 2026, due to a reduction in the number of directors certain stockholders can designate [4] - Mihas has been a member of the Board since October 2020 and provided valuable strategic guidance during his tenure [5][6] Group 3: Company Overview - Sotera Health is a leading global provider of end-to-end sterilization solutions, lab testing, and advisory services for the healthcare industry, operating through three businesses: Sterigenics, Nordion, and Nelson Labs [6]

Core Insights - Sotera Health Company reported strong financial results for the fourth quarter and full year of 2025, highlighting solid execution and increased demand for its services [4][7][8] Financial Performance - Fourth-quarter 2025 net revenues rose by 4.6% to $303 million, compared to $290 million in the fourth quarter of 2024, with a constant currency increase of 2.5% [2] - Full-year 2025 net revenues increased by 5.7% to $1.164 billion, up from $1.100 billion in 2024, with a constant currency growth of 5.2% [3][7] - Net income for the fourth quarter was $35 million, or $0.12 per diluted share, compared to $12 million, or $0.04 per diluted share in the same quarter of 2024 [2] - Full-year net income reached $78 million, or $0.27 per diluted share, compared to $44 million, or $0.16 per diluted share in 2024 [3] - Adjusted EBITDA for the fourth quarter increased by 2.7% to $157 million, with a constant currency growth of 0.5% [2] - Full-year adjusted EBITDA rose by 8.2% to $594 million, reflecting a constant currency growth of 7.8% [3] Business Segment Performance - Sterigenics segment reported fourth-quarter 2025 net revenues of $198 million, a 10.6% increase, with segment income of $110 million [6][8] - Nordion's fourth-quarter 2025 net revenues were $50 million, a decrease of 12.3%, attributed to cobalt-60 harvest schedule timing [9][10] - Nelson Labs experienced a 2.3% increase in fourth-quarter net revenues to $55 million, with segment income rising by 1.9% to $18 million [11][12] Management Transition - Effective April 1, 2026, Alex Dimitrief will transition to an advisory role, with Erika Ostrowski promoted to Senior Vice President and General Counsel [5][6] Balance Sheet and Liquidity - As of December 31, 2025, total debt was $2.2 billion, with cash and cash equivalents at $345 million, improving the net leverage ratio to 3.2x from 3.7x in 2024 [13][14] 2026 Outlook - The company anticipates net revenue growth of 5.0% to 6.5% and adjusted EBITDA growth of 5.5% to 7.0% for full-year 2026 [7][15]

Core Viewpoint - Sotera Health Company is set to release its financial results for Q4 and the full year of 2025 on February 24, 2026, before market opening, followed by a conference call to discuss the results and operational highlights [1]. Group 1 - The financial results will cover the period ending December 31, 2025 [1]. - A conference call is scheduled for 9:00 a.m. Eastern Time on the same day to discuss the results [1]. - A live webcast of the conference call will be available on the company's Investor Relations website, with a replay accessible later that day [2]. Group 2 - Sotera Health is recognized as a leading global provider of sterilization solutions, lab testing, and advisory services for the healthcare industry [4]. - The company operates through three business segments: Sterigenics, Nordion, and Nelson Labs [4]. - Sotera Health is dedicated to its mission of safeguarding global health [4].

Core Viewpoint - Sotera Health Company is experiencing solid growth, with revenue expected to exceed $1.16 billion in 2025, marking a year-over-year increase of at least 5.5% [2] Group 1: Company Overview - Sotera Health is a leading global provider of end-to-end sterilization solutions, lab testing, and advisory services for the healthcare industry [6] - The company operates through three business segments: Sterigenics, Nordion, and Nelson Labs [6] - The mission of Sotera Health is to safeguard global health [6] Group 2: Financial Performance - Revenue for 2025 is projected to surpass $1.16 billion, reflecting a growth of at least 5.5% year-over-year or 5.0% on a constant-currency basis [2] - This growth marks over two decades of consecutive year-over-year revenue increases, demonstrating the durability of the company's business model and financial profile [2] - Full-year results and the 2026 outlook will be shared on February 24, 2026 [2] Group 3: Investor Relations - A live webcast of the company's presentation at the J.P. Morgan Healthcare Conference will be available on the Investor Relations section of the company's website [2] - A replay of the presentation will be accessible within 48 hours and archived on the company's website [2]

Core Insights - Sotera Health Company reported strong financial results for the third quarter and first nine months of 2025, with significant revenue and income growth compared to the previous year [2][3][4]. Financial Performance - Third-quarter 2025 net revenues increased by 9.1% to $311 million, up from $285 million in the third quarter of 2024. On a constant currency basis, the increase was 8.0% [2][8]. - Net income for the third quarter of 2025 was $48 million, or $0.17 per diluted share, compared to $17 million, or $0.06 per diluted share in the same quarter of 2024 [2][8]. - Adjusted EBITDA for the third quarter of 2025 rose by 12.2% to $164 million, with an 11.2% increase on a constant currency basis [2][8]. - For the first nine months of 2025, net revenues grew by 6.2% to $860 million, with net income of $43 million, or $0.15 per diluted share, compared to $32 million, or $0.11 per diluted share in the same period of 2024 [3][8]. Business Segment Performance - Sterigenics segment reported net revenues of $193 million for the third quarter of 2025, a 9.8% increase, with segment income rising by 11.6% to $107 million [5][6]. - Nordion's net revenues increased by 22.4% to $63 million in the third quarter of 2025, with segment income up by 19.9% to $38 million [9][10]. - Nelson Labs experienced a decrease in net revenues by 5.0% to $56 million in the third quarter of 2025, but segment income increased by 1.9% to $19 million [11][12]. Outlook and Guidance - The company reaffirmed its 2025 revenue outlook, projecting growth in the range of 4.5% to 6.0% on a constant currency basis, and raised its Adjusted EBITDA growth outlook to 6.75% to 7.75% [4][16]. - The interest expense range was improved to $154 million to $158 million, and the tax rate applicable to Adjusted Net Income was adjusted to 29.00% to 31.00% [16][17]. Balance Sheet and Liquidity - As of September 30, 2025, Sotera Health had total debt of $2.2 billion and unrestricted cash of $299 million, with a Net Leverage Ratio improved to 3.3x [13][14]. - The company achieved a contractual net leverage target, resulting in a 25 basis point reduction in the interest rate on its First Lien Term Loan facility [14].

Core Viewpoint - Sotera Health Company will release its financial results for the third quarter ended September 30, 2025, on November 4, 2025, before market opening, followed by a conference call to discuss the results and operating highlights [1]. Company Overview - Sotera Health is a leading global provider of mission-critical end-to-end sterilization solutions, lab testing, and advisory services for the healthcare industry [3]. - The company operates through three business segments: Sterigenics, Nordion, and Nelson Labs [3]. - Sotera Health is dedicated to its mission of safeguarding global health [3]. Conference Call Details - The conference call will take place at 9:00 a.m. Eastern Daylight Time on November 4, 2025 [1]. - Participants can join the call by dialing 1-844-481-2916 (toll-free in the U.S.) or 1-412-317-0709 for international calls [2]. - A live webcast of the conference call will be available on the company's website, along with accompanying materials, and a replay will be accessible later that day [2].

Core Insights - Sotera Health Company reported a 6.4% increase in net revenues for Q2 2025, reaching $294 million compared to $277 million in Q2 2024, with a constant currency increase of 6.0% [2][6] - The company experienced a net income of $8 million, or $0.03 per diluted share, which includes a pending settlement of approximately $34 million related to ethylene oxide claims [2][3] - Adjusted EBITDA for Q2 2025 rose by 9.8% to $151 million, with an adjusted earnings per diluted share of $0.20, an increase of $0.01 from the previous year [2][6] Financial Performance - For the first half of 2025, net revenues increased by 4.6% to $549 million, compared to $525 million in the same period of 2024, with a constant currency increase of 5.3% [3][6] - The company reported a net loss of $5 million for the first half of 2025, which includes settlements of approximately $31 million and $34 million related to ethylene oxide claims [3][6] - Adjusted EBITDA for the first half of 2025 increased by 9.3% to $273 million, with adjusted EPS rising by $0.01 to $0.33 compared to the first half of 2024 [3][6] Business Segment Performance - Sterigenics segment revenues grew by 10.5% to $195 million in Q2 2025, with segment income increasing by 11.3% to $108 million [5] - Nordion's net revenues increased by 2.9% to $42 million in Q2 2025, with segment income slightly rising to $23 million [8] - Nelson Labs experienced a 3.3% decrease in net revenues to $57 million in Q2 2025, but segment income increased by 13.9% to $20 million [10] Outlook and Guidance - The company raised its full-year 2025 revenue outlook to a growth range of 4.5% - 6.0% from a previous range of 4.0% - 6.0% [6][14] - Adjusted EBITDA growth outlook was also raised to 6.0% - 7.5% from 4.5% - 6.5% [6][14] - The expected tax rate applicable to adjusted net income improved to a range of 31.5% - 33.5% from 33% - 35% [14] Balance Sheet and Liquidity - As of June 30, 2025, Sotera Health had total debt of $2.3 billion and unrestricted cash of $332 million, compared to $2.3 billion in total debt and $277 million in cash at the end of 2024 [12] - The company's net leverage ratio improved to 3.5x as of Q2 2025, down from 3.7x at the end of 2024 [12][14]